fcell-09-616271 June 23, 2021 Time: 12:21 # 1 ORIGINAL RESEARCH published: 24 June 2021 doi: 10.3389/fcell.2021.616271 Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma Anran Zhang1†, Jinpo Yang2†, Chao Ma3,4*, Feng Li3,5 and Huan Luo3 1 Department of Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Henan University People’s Hospital, Zhengzhou, China, 2 Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China, 3 Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany, 4 Berlin Institute of Health Center for Regenerative Edited by: Therapies and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin, Berlin, Jawed Akhtar Siddiqui, Germany, 5 Department of Surgery, Competence Center of Thoracic Surgery, Charité University Hospital Berlin, Berlin, University of Nebraska Medical Germany Center, United States Reviewed by: Tao Jiang, Background: Lung adenocarcinoma (LUAD) is the most common subtype of non- University of Illinois small cell lung cancer. Ferroptosis is a newly recognized process of cell death, which is at Urbana-Champaign, United States Concetta Saponaro, different from other forms of cell death in morphology, biochemistry, and genetics, and Istituto Tumori Bari Giovanni Paolo II, has played a vital role in cancer biology. This study aimed to identify a ferroptosis-related Istituto Nazionale dei Tumori (IRCCS), gene signature associated with LUAD prognosis. Italy *Correspondence: Methods: Dataset TCGA-LUAD which came from the TCGA portal was taken as Chao Ma the training cohort. GSE72094 and GSE68465 from the GEO database were treated
[email protected] orcid.org/0000-0003-1444-4668 as validation cohorts.